individual patient lifethreaten sever deficit disease petit unit state food drug administer fda physician expand access ea drug clinic trial reach full approve singlepati investing new ind applied admit recent state fewer lawssocal right tri legislationallow approach company directly prior pathway provide potent differ permit entire group certain review focus special category ind intend multiple patients intermediategroup widespreadtreat india well emerge author use biology product eg vaccine public health emerge 